One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries
doi : 10.1056/NEJMp2412955
Volume 392 No. 6 February 6, 2025
Pulling Out the Rug on Informed Consent — New Legal Threats to Clinicians and Patients
doi : 10.1056/NEJMp2413570
The Future of Gender-Affirming Care — A Law and Policy Perspective on the Cass Review
doi : 10.1056/NEJMp2413747
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
doi : 10.1056/NEJMoa2410316
Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial
doi : 10.1056/NEJMoa2407379
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53
doi : 10.1056/NEJMoa2411507
Way Stations in Progress — Burgeoning Treatment Options for IgA Nephropathy
doi : 10.1056/NEJMe2413288
Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman’s Disease
doi : 10.1056/NEJMc2412494
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
doi : 10.1056/NEJMc2414705
